secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-116703
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Q3 net loss $20.8M; cash $422.9M; APG777 Phase 1 dosed ahead of schedule
-------------------------------------------------------------------------------

- Net loss $20.8M in Q3 2023 vs $19.7M in Q3 2022; R&D spend rose to $17.1M from $9.9M.
- Cash $422.9M as of Sept 30, 2023; expected runway into Q4 2026 after $345M IPO in July.
- Phase 1 trial of APG777 begun ahead of schedule; initial PK/safety data from healthy volunteers expected mid-2024.
- Development candidate for APG808 (anti-IL-4Rα) finalized in Q4 2023; preclinical half-life up to 26 days vs 12 days for DUPIXENT.
- Mark C. McKenna appointed Chairman; Matt Batters joined as General Counsel in August 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/0001104659-23-116703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923116703/tm2330055d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer